Evidence map›Paper›PMID 34423596›Full record

ArticleJournal of veterinary science2021

Ustekinumab pharmacokinetics after subcutaneous administration in swine model.

Tomasz Grabowski, Artur Burmańczuk, Rafał Derlacz, Tadeusz Stefaniak, Anna Rząsa, Jacek Borkowski

Open access · goldAbstract read
In one paragraph

Article in Journal of veterinary science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Tomasz GrabowskiPolpharma Biologics SA, 80-172 Gdańsk, Poland.ORCID https://orcid.org/0000-0002-3077-9698
Artur BurmańczukSub-Department of Pharmacology, Toxicology and Environmental Protection, Faculty of Veterinary Medicine, University of Life Sciences, 20-033 Lublin, Poland. artur.burmanczuk@up.lublin.pl.ORCID https://orcid.org/0000-0002-2354-7696
Rafał DerlaczPolpharma Biologics SA, 80-172 Gdańsk, Poland.ORCID https://orcid.org/0000-0002-8254-3521
Tadeusz StefaniakDepartment of Immunology, Pathophysiology and Veterinary Preventive Medicine, Wroclaw University of Environmental and Life Sciences, 50-375 Wrocław, Poland.ORCID https://orcid.org/0000-0002-8982-211X
Anna RząsaDepartment of Immunology, Pathophysiology and Veterinary Preventive Medicine, Wroclaw University of Environmental and Life Sciences, 50-375 Wrocław, Poland.ORCID https://orcid.org/0000-0002-0903-3445
Jacek BorkowskiDepartment of Physiology and Biochemistry, University School of Physical Education in Wroclaw, 51-612 Wrocław, Poland.ORCID https://orcid.org/0000-0002-5535-5955
SciencePharma (Poland) · PLWrocław University of Environmental and Life Sciences · PLUniversity of Life Sciences in Lublin · PLWroclaw University of Health and Sport Sciences · PL

Funding

Narodowe Centrum Badań i Rozwoju POIR.01.01.01-00-0407/17-00
6 · The paper itself

Abstract

backgroundDue to multiple similarities in the structure and physiology of human and pig skin, the pig model is extremely useful for biological drug testing after subcutaneous administration. Knowledge of the differences between subcutaneous injection sites could have a significant impact on the absorption phase and pharmacokinetic profiles of biological drugs.

objectivesThis study aimed to analyze the impact of administration site on pharmacokinetics and selected biochemical and hematological parameters after a single subcutaneous administration of ustekinumab in pigs. Drug concentrations in blood plasma were analyzed by enzyme-linked immunosorbent assay. Pharmacokinetic analyses were performed based on raw data using Phoenix WinNonlin 8.1 software and ThothPro v 4.1.

methodsThe study included 12 healthy, female, large white piglets. Each group received a single dose of ustekinumab given as a 1 mg/kg subcutaneous injection into the internal part of the inguinal fold or the external part of the inguinal fold.

resultsThe differences in absorption rate between the internal and external parts of the inguinal fold were not significant. However, the time of maximal concentration, clearance, area under the curve calculated between zero and mean residence time and mean residence time between groups were substantially different (

conclusionsHealthy breeding pigs are a relevant model to study the pharmacokinetic profile of subcutaneously administered ustekinumab.

Indexed as

AnimalsBiological AvailabilityDermatologic AgentsFemaleHumansInjections, SubcutaneousModels, AnimalSus scrofaUstekinumabDermatologic AgentsUstekinumabbiologicspharmacokineticsskinSwineustekinumab

Identifiers

PMID34423596
PMCPMC8460463
OpenAlexW3169651500

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.